Tuesday links: pernicious and permanent
Tadas Viskanta
Abnormal Returns
11 months ago
2 MIN READ
Strategy
- Stop dissing standard deviation as a risk measure. (morningstar.com)
- ETF is not a euphemism for good investment. (etf.com)
Finance
- Can Citi ($C) ever catch up to its peers? (wsj.com)
- Where did all the Chinese IPOs go? (nytimes.com)
- The Series A crunch is here. (tomtunguz.com)
Weight loss
- Novo Nordisk ($NVO) is building a new plant in North Carolina to manufacture weight loss drugs. (axios.com)
- Wegovy has been approved for sale in China. (semafor.com)
- The use of tirzepatide can apparently treat sleep apnea. (newatlas.com)
- Asking someone about weight loss these days is fraught. (wapo.st)
Economy
- The March Case-Shiller home prices indices showed a 6.3% year-over-year increase. (calculatedriskblog.com)
- How home prices will filter through to CPI. (bonddad.blogspot.com)
Earlier on Abnormal Returns
- Research links: training and testing. (abnormalreturns.com)
- What you missed in our Tuesday linkfest. (abnormalreturns.com)
- Adviser links: a sense of purpose. (abnormalreturns.com)
- Are you a financial adviser looking for some out-of-the-box thinking? Then check out our weekly e-mail newsletter. (newsletter.abnormalreturns.com)
Mixed media
Terms and Conditions
This content, which contains security-related opinions and/or information, is provided for informational purposes only and should not be relied upon in any manner as professional advice, or an endorsement of any practices, products or services. There can be no guarantees or assurances that the views expressed here will be applicable for any particular facts or circumstances, and should not be relied upon in any manner. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment.
The commentary in this “post” (including any related blog, podcasts, videos, and social media) reflects the personal opinions, viewpoints, and analyses of the Ritholtz Wealth Management employees providing such comments, and should not be regarded the views of Ritholtz Wealth Management LLC. or its respective affiliates or as a description of advisory services provided by Ritholtz Wealth Management or performance returns of any Ritholtz Wealth Management Investments client.
References to any securities or digital assets, or performance data, are for illustrative purposes only and do not constitute an investment recommendation or offer to provide investment advisory services. Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others.
Please see disclosures here.
